A Phase 3 interventional study of Valsartan/amlodipine 80/5 mg and Valsartan 80 mg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-04-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 15th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 67th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,134 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 24th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 103rd registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan/amlodipine 80/5 mg
Drug: Valsartan 80 mg
Drug: Valsartan 160 mg
1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
Time frame: Baseline to end of study (Week 8)
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)
A diastolic blood pressure response was defined as a msDBP \< 90 mmHg or a ≥ 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
Time frame: Baseline to end of study (Week 8)
Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)
Diastolic blood pressure control was defined as a msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
Time frame: End of study (Week 8)
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
Overall blood pressure control rate was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
Time frame: End of study (Week 8)
A total of 1134 patients were enrolled into the single-blind period of the study, and 216 (19%) were discontinued. In total, 918 patients were randomized to the three treatment groups.
| Milestone | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 0 | 1134 | 0 |
| Completed | 0 | 918 | 0 |
| Not completed | 0 | 216 | 0 |
| Withdrew: Adverse event | 0 | 9 | 0 |
| Withdrew: Lack of efficacy | 0 | 5 | 0 |
| Withdrew: Subject no longer requires study drug | 0 | 151 | 0 |
| Withdrew: Protocol violation | 0 | 16 | 0 |
| Withdrew: Withdrawal by subject | 0 | 27 | 0 |
| Withdrew: Lost to follow-up | 0 | 8 | 0 |
| Milestone | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 308 | 307 | 303 |
| Completed | 293 | 293 | 285 |
| Not completed | 15 | 14 | 18 |
| Withdrew: Adverse event | 6 | 0 | 5 |
| Withdrew: Unsatisfactory therapeutic effect | 1 | 2 | 1 |
| Withdrew: Protocol deviation | 1 | 2 | 1 |
| Withdrew: Subject withdrew consent | 4 | 6 | 9 |
| Withdrew: Lost to follow-up | 3 | 4 | 2 |
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
| mmHg | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | -10.8 ± 0.42 | -6.3 ± 0.42 | -7.2 ± 0.42 |
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
| mmHg | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | -12.5 ± 0.61 | -6.0 ± 0.62 | -7.7 ± 0.62 |
A diastolic blood pressure response was defined as a msDBP \< 90 mmHg or a ≥ 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
| Percentage of patients | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8) | 77.9 | 57.8 | 66.6 |
Diastolic blood pressure control was defined as a msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
| Percentage of patients | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8) | 74.4 | 53.6 | 64.2 |
Overall blood pressure control rate was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.
| Percentage of patients | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8) | 70.5 | 44.1 | 58.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan/Amlodipine 80/5 mg | — | 4/308 (1.3%) | 0/308 (0%) |
| Valsartan 80 mg | — | 0/307 (0%) | 0/307 (0%) |
| Valsartan 160 mg | — | 4/303 (1.3%) | 0/303 (0%) |
| Event | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Cerebral infarctionNervous system disorders | 0/308 | 0/307 | 3/303 |
| LeukopeniaBlood and lymphatic system disorders | 0/308 | 0/307 | 1/303 |
| Retinal haemorrhageEye disorders | 1/308 | 0/307 | 0/303 |
| Abdominal injuryInjury, poisoning and procedural complications | 1/308 | 0/307 | 0/303 |
| Liver function test abnormalInvestigations | 1/308 | 0/307 | 0/303 |
| Transient ischaemic attackNervous system disorders | 1/308 | 0/307 | 0/303 |
| Age Continuous(years) | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Mean | 51.6 ± 10.8 | 51.7 ± 8.9 | 51.2 ± 9.6 | 51.5 ± 9.8 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine 80/5 mg | Valsartan 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|---|
| Female | 127 | 115 | 104 | 346 |
| Male | 181 | 191 | 198 | 570 |
The record gives a start of Jan 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan